Home LiteratureArticle Details
PMID: 522637 Published · ppublish English Clinical Trial Controlled Clinical Trial Journal Article

The effect of beta-blockade in ski-jumpers.

Medicine and science in sports ·Vol. 11 ·No. 3 ·1979-00-00 ·Pages 266-9

Videman T, Sonck T, Jänne J

Abstract

Nine ski-jumpers from the Finnish Olympic team were given 40 mg of oxprenolol or placebo on a cross-over double-blind basis when participating in four internal competitions. Six ski-jumpers improved their performances when on oxprenolol. The improvement was mainly seen in the lengthening of the jumps. The tachycardia, apparently evoked by the emotional and physical strain associated with the actual jump, approached rather extreme levels (up to 170 beats/min) immediately after landing. The enhancement in the heart rate was effectively prevented by a gentle beta-blockade. The most common unwanted effect recorded was numbness in the legs after climbing up to the tower platform, reported 9 times out of 18 possible occasions after oxprenolol but never after placebo. The fact that three of the jumpers (out of 9) performed worse when on oxprenolol makes the toxic/benefit ratio (1:2) unacceptably high for the medication.

MeSH Terms
Double-Blind Method Heart Rate/drug effects Humans Oxprenolol/adverse effects,pharmacology Physical Exertion/drug effects Placebos Skiing Sports Medicine
Chemicals
Placebos Oxprenolol
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Videman T
Sonck T
Jänne J
Article Info
Journal
Medicine and science in sports
Abbr.
Med Sci Sports
ISSN
0025-7990
Published
1979-00-00
Pages
266-9
Language
English
Region
United States
NLM ID
0203246
Subset
IM
External Links
PubMed source
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com